Blood test could shorten antibiotic course for newborns with sepsis

NCT ID NCT03730636

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether measuring a blood marker called procalcitonin (PCT) could help doctors decide when to stop antibiotics in newborns with late-onset sepsis. Over 500 newborns were included, and the goal was to reduce antibiotic use by 30% without increasing infection recurrence or death. The approach could lead to shorter treatment and fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: procalcitonin measurement (blood test)
What this could lead to: If successful, this approach could shorten antibiotic treatment in newborns with sepsis, reducing side effects and hospital stays.
What could go wrong: This is a completed trial, but results may not apply to all hospitals or newborns. The marker may not always accurately guide treatment, risking undertreatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LATE ONSET SEPSIS OF NEONATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis neonatal sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPSIS

Contacts and locations

Locations

Department of Neonatology Bretonneau Hospital

Paris, Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.